

SPECTRUM PHARMACEUTICALS INC  
Form 8-K  
January 26, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): January 26, 2012**

**SPECTRUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction)

**001-35006**  
(Commission)

**93-0979187**  
(IRS Employer)

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

(State of incorporation)

(File Number)

(Identification No.)

**11500 S. Eastern Ave., Ste. 240, Henderson, NV 89052**  
(Address of principal executive offices, including zip code)

**Registrant's telephone number, including area code: (702) 835-6300**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On January 26, 2012, Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. (the Company) remarked in an interview with a member of the press that the Company currently anticipates that fourth quarter revenues will be the same or better than the Company's third quarter sales of \$51 million. As with all forward looking statements, there can be no assurance that such results will be achieved.

*The information in this Current Report on Form 8-K is furnished pursuant to Item 7.01 and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.*

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 26, 2012

**SPECTRUM PHARMACEUTICALS, INC.**

By: /s/ Brett L. Scott  
Brett L. Scott  
Senior Vice President and Acting Chief

Financial Officer